Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017' by Checchi et al
- PMID: 31320396
- DOI: 10.1136/sextrans-2019-054101
Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017' by Checchi et al
Keywords: epidemiology (general); genital warts; hpv; vaccination.
Conflict of interest statement
Competing interests: VB and SW are employees of the GSK group of companies. VB also holds shares in the GSK group of companies. GlaxoSmithKline Biologicals SA took in charge all costs associated with the development and publication of this short letter.
Comment in
-
Response to Berlaimont and Welby.Sex Transm Infect. 2019 Nov;95(7):553. doi: 10.1136/sextrans-2019-054148. Epub 2019 Jul 18. Sex Transm Infect. 2019. PMID: 31320395 No abstract available.
Comment on
-
Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.Sex Transm Infect. 2019 Aug;95(5):368-373. doi: 10.1136/sextrans-2018-053751. Epub 2019 Feb 5. Sex Transm Infect. 2019. PMID: 30723186
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical